Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Chronic Graft-Versus-Host Disease (cGVHD)
NCT02759731Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2016
- Primary completion
- Jun 2022
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of baricitinib in chronic graft-versus-host disease (cGVHD), sponsored by National Cancer Institute. Primary endpoints: Dose-Limiting Toxicities at 4 weeks, Serious and/or Non-Serious Grades 3, 4, and/or 5 Adverse Events Due to Drug at 48 weeks and 1 more. Started Nov 2016; status: completed.
02
Drugs
baricitinib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT02759731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02759731.